HC Wainwright maintained a Buy rating for MannKind on August 13, 2026. The firm revised its FY2029 EPS estimate to $0.27 from $0.39. Analysts also initiated a FY2030 earnings projection of $0.68 per share. Current consensus estimates for the full year forecast a loss of ($0.08) per share.
Seeking Alpha issued a Strong Buy rating, citing two recent FDA approvals as transformative catalysts. The agency approved Afrezza for pediatric use. Regulators also cleared the FUROSCIX ReadyFlow device. These milestones position the company at a critical inflection point for potential exponential growth.
A recent $50 million private placement strengthened the company's financial position. MannKind now holds sufficient liquidity to fund operations and commercial launches for over two years.